AIM ImmunoTech Inc. (NYSE American: AIM) announced plans to advance its drug Ampligen into a Phase 3 clinical trial for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE